The short answer
An MHRA marketing authorisation establishes that a medicine is safe, effective and of adequate quality. It says nothing about whether the NHS will pay for it. That is decided separately by NICE, which assesses cost-effectiveness, and for obesity medicines the size of the eligible population makes those appraisals unusually difficult.
Key facts
- MHRA decides
- Safety, efficacy, quality (the licence)
- NICE decides
- Cost-effectiveness (NHS funding)
- Common metric
- Cost per quality-adjusted life year (QALY)
- Obesity-specific difficulty
- Very large eligible population
- Typical outcome
- Restricted eligibility or managed access
- Orforglipron guidance
- Expected 27 January 2027 (first due 18 November 2026)
Two decisions, two bodies, two questions
The MHRA asks whether a medicine works and is safe enough to be sold. NICE asks whether the health benefit it delivers justifies its cost relative to everything else the NHS could spend that money on. A medicine can pass the first comfortably and fail the second, and the gap between the two decisions is often a year or more.
What a QALY is and why it governs the outcome
NICE appraisals are built on cost per quality-adjusted life year, a measure combining how long a treatment extends life with how much it improves the quality of that life. A threshold range is applied as a guide rather than a hard rule. The calculation depends heavily on modelled long-term outcomes, which is where obesity medicines become contentious. The benefit accrues over decades and has to be projected rather than observed.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why obesity medicines are hard appraisals
The eligible population is enormous. A medicine licensed for BMI of 30 or above, or 27 to 30 with a comorbidity, potentially applies to millions of people in England alone. Even a modest cost per patient becomes a very large aggregate budget impact, and budget impact is assessed separately from cost-effectiveness. This is why previous incretin appraisals have produced tightly restricted eligibility, specialist-service requirements or managed-access agreements rather than open prescribing.
The discontinuation problem inside the model
Cost-effectiveness modelling has to account for what happens when treatment stops, and the evidence there is unambiguous: substantial regain follows cessation across the class. A model assuming sustained benefit after stopping produces a very different answer from one assuming most of the reduction is lost. This is one reason maintenance-dosing trial data matter to funding decisions as much as to clinicians.
What to expect next
Guidance on orforglipron was due on 18 November 2026. After a second committee meeting on 10 November 2026, NICE moved the expected date to 27 January 2027. Possible outcomes range from a recommendation with restricted eligibility, through managed access, to a negative recommendation. A positive recommendation does not produce immediate prescribing either. Implementation follows, so NHS prescribing would start some time after the guidance even in the favourable case.
Frequently asked questions
If the MHRA approved it, why will the NHS not prescribe it?
Because those are different questions. The MHRA licenses on safety and efficacy; NICE decides funding on cost-effectiveness, in a separate appraisal that comes afterwards.
What is a QALY?
A quality-adjusted life year, combining length and quality of life into one measure so treatments across different conditions can be compared on cost per unit of benefit.
Does a positive NICE recommendation mean immediate availability?
No. Implementation follows the recommendation, and obesity medicines have typically come with eligibility restrictions and service requirements.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- CagriSema FDA Filing: Where the Review StandsNovo Nordisk filed CagriSema with the FDA in December 2025 on the REDEFINE programme. A decision is expected in Q4 2026. What the trials reported.
- TRIUMPH-5: The Retatrutide vs Tirzepatide Head-to-HeadTRIUMPH-5 randomises 800 adults to retatrutide or tirzepatide over Phase 3. Primary completion is November 2026 - the first direct comparison of the two.
- TRIUMPH-6: Maintenance of Weight ReductionTRIUMPH-6 tests whether reduction is sustained on maintenance dosing. 643 participants, primary completion April 2028 - the field's key question is years away.
- Retatrutide Expanded Access: What It Actually IsA pre-approval expanded access record for retatrutide is listed as available. What expanded access means, who it is for, and what it is emphatically not.
- The Compounded GLP-1 CrackdownThe FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulks List in April 2026, closing the last legal route for mass compounding.